Thailand Peptides
Get in Contact
Catalog
PeptidesCategories
Research
CompareInformation
Calculator
Get in Contact
Comparison · Cognitive & Nootropic

Cerebrolysin vs Selank

Cerebrolysin and Selank target cognitive function from completely different angles. Cerebrolysin is a clinical-grade porcine peptide mixture used as an infusion course in stroke and dementia. Selank is an intranasal anxiolytic nootropic based on tuftsin.

Bangkok research desk ·

Side-by-side

Cerebrolysin Selank
MechanismPorcine peptide mixture; neurotrophic factor-like activity.Tuftsin analog; anxiolytic via enkephalin and GABAergic modulation.
Half-lifeCourse-based.Short (intranasal).
Dose5-30 mL IM or IV.250-500 mcg × 2 daily intranasal.
Cycle10-20 days daily; 2×/year.14 days on / 14 off.
Research contextStroke and dementia; CARS, CASTA trials1.Anxiolytic and nootropic; modulates hippocampal transcriptome2.
Cost tierHigh.Low-to-mid.

Cerebrolysin and Selank almost never substitute for each other in research protocols. Cerebrolysin is a clinical-grade neurotrophic course used in acute stroke recovery and dementia1. Selank is an intranasal anxiolytic peptide used in cognitive-enhancement and stress-resilience research2. They appear together in comparison articles because both appear in broader nootropic surveys, not because they answer the same research question.

Cerebrolysin's clinical footprint is substantial. Registered in Europe and Asia, with CARS and CASTA being the most-cited randomised trials, it is administered as a daily 10-20 day infusion course, typically repeated once or twice per year. Volume is 5-30 mL per administration. This is a clinical procedure, not a self-administered peptide.

Selank is a short intranasal peptide. Typical dosing is 250-500 mcg twice daily, self-administered, on a 14-day on / 14-day off cycle. Research leans toward anxiolytic and attention-related endpoints. The two compounds exist in different research worlds. When both appear on a study design, they are usually complementary rather than comparative: Cerebrolysin as the acute neurotrophic intervention, Selank as a longer-term cognitive support tool.

See nootropic peptide mechanisms for the class-level comparison across Cerebrolysin, Semax, Selank, and DSIP.

Frequently asked

Can Selank substitute for Cerebrolysin?
No. Cerebrolysin is a clinical-grade acute intervention; Selank is a self-administered research peptide with a much narrower mechanism. They do not overlap in research indication.
Can they be used together?
In theory yes, with non-overlapping mechanisms and administration routes. In practice Cerebrolysin is course-based and Selank is continuous; any combined protocol should sequence them with care.
Which has stronger clinical registration?
Cerebrolysin has the broader registration (Europe, Asia, Latin America). Selank is registered in Russia. Neither is FDA-approved.
Research desk
Ordering both Cerebrolysin and Selank for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.
Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

References

  1. Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS). Stroke. 2016. PMID: 26564102
  2. Kolomin T, et al. Transcriptomic response of rat hippocampus and spleen cells to Selank. Dokl Biochem Biophys. 2010. PMID: 20380151

All references verified against PubMed via NCBI E-utilities.